WASHINGTON: A fresh tariff timeline unveiled by President Donald Trump on generic pharmaceutical imports is set to reverberate most sharply through one relationship in particular: the deep trade partnership between the United States and India, the world’s largest supplier of generic medicines to the American market. Indian pharmaceutical manufacturers currently supply roughly half of all The post Trump’s generic drug tariff plan puts US-India pharma ties to test appeared first on MM News.



